Treace Medical Concepts Inc
NASDAQ:TMCI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Treace Medical Concepts Inc
NASDAQ:TMCI
|
US |
|
A
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SSE:600063
|
CN |
|
Brambles Ltd
ASX:BXB
|
AU |
|
Mizrahi Tefahot Bank Ltd
TASE:MZTF
|
IL |
|
C
|
Cognyte Software Ltd
NASDAQ:CGNT
|
IL |
|
Robo.ai Inc
NASDAQ:AIIO
|
AE |
|
Mayfield Childcare Ltd
ASX:MFD
|
AU |
|
Bigben Interactive SA
PAR:BIG
|
FR |
Treace Medical Concepts Inc
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 248 full-time employees. The company went IPO on 2021-04-23. The firm is focused on strategic product development activities that improve surgical efficiencies and patient outcomes. The firm's proprietary Lapiplasty 3-dimensional (3D) Bunion Correction System, which is a combination of instruments, implants and surgical methods designed to correct all three dimensions of the bunion deformity, address the root cause of the bunion deformity. The Lapiplasty System combines novel surgical approach, the Lapiplasty Procedure, with its procedural instrumentation and single-use implant kits. The Lapiplasty Procedure is designed to rotate the entire metatarsal bone into normal anatomical position in all three dimensions, eliminating the bump and restoring normal anatomy. The Lapiplasty Procedure can be performed in either hospital outpatient or ambulatory surgery center settings. The firm's brands include Lapiplasty, Fast Grafter and Plantar Python.
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 248 full-time employees. The company went IPO on 2021-04-23. The firm is focused on strategic product development activities that improve surgical efficiencies and patient outcomes. The firm's proprietary Lapiplasty 3-dimensional (3D) Bunion Correction System, which is a combination of instruments, implants and surgical methods designed to correct all three dimensions of the bunion deformity, address the root cause of the bunion deformity. The Lapiplasty System combines novel surgical approach, the Lapiplasty Procedure, with its procedural instrumentation and single-use implant kits. The Lapiplasty Procedure is designed to rotate the entire metatarsal bone into normal anatomical position in all three dimensions, eliminating the bump and restoring normal anatomy. The Lapiplasty Procedure can be performed in either hospital outpatient or ambulatory surgery center settings. The firm's brands include Lapiplasty, Fast Grafter and Plantar Python.
Revenue Decline: Q4 revenue was $62.5 million, down 9% year-over-year, primarily due to a shift toward lower-priced products.
Full-Year Guidance: 2026 revenue is expected to be between $200 million and $212 million, representing a 6% to 0% decrease versus 2025.
Improved Profitability: Adjusted EBITDA loss narrowed to $3.9 million in 2025, a 64% improvement over the prior year, and further EBITDA losses of $4–6 million are expected for 2026.
Reduced Cash Burn: Cash usage in 2025 was $27.3 million, a 46% reduction from 2024, with another 50% reduction in cash burn targeted for 2026.
Product Expansion: Multiple new bunion technologies launched in 2025, with strong early adoption and plans to launch further products in 2026 to expand the addressable market.
Market Conditions: Management described ongoing softness and deferrals in the foot and ankle market, with mixed product pricing acting as a headwind, but continued share gains expected.
Case Volume Growth: Q4 saw acceleration in procedure volumes, with over 25% of surgeons already using the new systems.
Strategic Focus: The company is prioritizing deeper penetration with the existing surgeon base, while new products are expected to attract more users and broaden TAM.
